Related Experiment Video
Updated: Feb 22, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Developmental Pharmacokinetics in Neonates: Maturational Changes and Beyond
Karel Allegaert1, Paola Mian1, John N van den Anker2
1Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands.
Insights
Understanding neonatal pharmacokinetics (PK) and pharmacodynamics (PD) is crucial for safe drug therapy. This study details how maturational and non-maturational factors influence drug behavior in neonates.
Area of Science:
- Neonatal pharmacology
- Pediatric pharmacokinetics
- Drug metabolism and elimination
Background:
- Effective pharmacotherapy in neonates requires understanding drug pharmacokinetics (PK) and pharmacodynamics (PD).
- Neonatal populations exhibit unique PK and PD profiles due to developmental and disease-related factors.
Purpose of the Study:
- To describe general PK aspects of drug absorption, distribution, metabolism, and elimination (ADME) in neonates.
- To emphasize the impact of both maturational and non-maturational covariates on PK variability.
- To illustrate these concepts with specific drug examples.
Main Methods:
- Review of developmental PK principles in neonates.
- Analysis of maturational covariates (age, weight) affecting ADME processes.
- Examination of non-maturational covariates (disease, treatment, genetics) influencing PK.
Main Results:
- Neonatal ADME processes undergo maturation, influenced by various covariates.
- Maturational covariates include age and weight-dependent changes.
- Non-maturational covariates encompass disease, environment, co-medications, and genetic background.
Conclusions:
- Further research should integrate existing knowledge and collect data on non-maturational covariates.
- Linking PK data with PD is essential for predicting drug effects and side effects.
- Enhanced understanding of neonatal PK/PD is clinically significant for optimizing drug therapy.
Background:
Effective and safe pharmacotherapy in an individual neonate necessitates understanding the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a specific drug together with the characteristics of this neonate.
Methods:
Developmental PK hereby provides estimates of the concentration-time profile. Multiple maturational, disease and treatment related differences can result in differences in PK and probably also in PD in neonates compared to other populations. All these PK processes (absorption, distribution, metabolism and elimination, ADME) display maturation but are also affected by non-maturational covariates. Maturational covariates relate to age or weight dependent changes, while non-maturational covariates relate to variables in disease, environment, treatment - including co-medications - or genetic background.
Results:
We will describe general PK related aspects of ADME in neonates with emphasis on both maturational and non-maturational covariates of the variability observed, followed by compound specific illustrations (tramadol, amikacin) to further underscore the impact and interaction of these maturational and non-maturational changes.
Conclusion:
Future efforts should focus on integration of the already available knowledge and the collection of data on the impact of non-maturational covariates. These kinds of PK efforts will become clinically important when subsequently linked to PD, ultimately covering both wanted effects and undesired side-effects.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Factors Affecting Drug Response: Overview

